» Articles » PMID: 30177687

Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification

Overview
Journal Sci Rep
Specialty Science
Date 2018 Sep 5
PMID 30177687
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

We successfully determined the difference of immune microenvironments between pNENs and pancreatic ductal adenocarcinomas (PDACs), and the histology-dependent variability among pNENs using multispectral fluorescent imaging system. Tumour tissue samples including 52 pNENs and 18 PDACs were investigated. The tumour-infiltrating lymphocytes (TILs), their PD-1 and PD-L1 expression in the pNENs were comprehensively and quantitatively analysed and were subsequently compared with those in PDACs. A principal component analysis revealed that the tissue immune profile is related to tumour histology, with distinct groups being observed for NETs, NECs, and PDACs. While NECs and some PDACs had hot immune microenvironments with abundant TILs, NETs had a cold immune microenvironment with few TILs. Moreover, in NETs, the numbers of intraepithelial PD-1 T cells and PD-L1 Type-II macrophages were elevated according to the grade. Univariate analysis revealed that lymph node metastasis, grade, stage, PD-1 T cells, and PD-L1 Type-II macrophages were predictors for recurrence-free survival (RFS), while grade and PD-1 T cells were prognostic factors for overall survival (OS). We also showed that PD-1 T cells and PD-L1 Type-II macrophages were associated with worse outcome in pNENs. Our results support the WHO 2017 tumour classification criteria, which distinguish between G3 NETs and NECs.

Citing Articles

Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut.

Garcia-Torralba E, Garcia-Lorenzo E, Doger B, Spada F, Lamarca A Cancers (Basel). 2024; 16(14).

PMID: 39061170 PMC: 11275146. DOI: 10.3390/cancers16142530.


Endoscopic loco-regional treatment in controlling pancreatic neuroendocrine tumors (PNETs) behavior: a case series and literature review.

Lesmana C Clin J Gastroenterol. 2024; 17(4):754-759.

PMID: 38536602 DOI: 10.1007/s12328-024-01959-2.


Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy-A Systematic Review.

Chmiel P, Rychcik-Pazyrska P, Stec R Cancers (Basel). 2023; 15(21).

PMID: 37958406 PMC: 10648089. DOI: 10.3390/cancers15215232.


Correlation of Neuroendocrine Differentiation with a Distinctively Suppressive Immune Microenvironment in Gastric Cancer.

Zou Y, Li D, Yu X, Zhou C, Zhu C, Yuan Y Neuroendocrinology. 2023; 114(2):192-206.

PMID: 37827134 PMC: 10836751. DOI: 10.1159/000534427.


Progress in immunotherapy for neuroendocrine neoplasm of the digestive system.

Pan W, Zhang X, Hao S, Han W World J Gastroenterol. 2023; 29(26):4174-4185.

PMID: 37475845 PMC: 10354576. DOI: 10.3748/wjg.v29.i26.4174.


References
1.
Igari F, Sato E, Horimoto Y, Takahashi Y, Isomura T, Arakawa A . Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. Hum Pathol. 2017; 70:129-138. DOI: 10.1016/j.humpath.2017.10.020. View

2.
Dong Z, Zhang C, Li Y, Su J, Xie Z, Liu S . Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. J Thorac Oncol. 2017; 13(1):85-96. DOI: 10.1016/j.jtho.2017.10.020. View

3.
Balar A, Weber J . PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017; 66(5):551-564. PMC: 11028560. DOI: 10.1007/s00262-017-1954-6. View

4.
Stanton S, Adams S, Disis M . Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016; 2(10):1354-1360. DOI: 10.1001/jamaoncol.2016.1061. View

5.
Yachida S, Vakiani E, White C, Zhong Y, Saunders T, Morgan R . Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012; 36(2):173-84. PMC: 3261427. DOI: 10.1097/PAS.0b013e3182417d36. View